Next Article in Journal
Prediction of Hepatocellular Carcinoma Development after Hepatitis C Virus Eradication Using Serum Wisteria floribunda Agglutinin-Positive Mac-2-Binding Protein
Previous Article in Journal
Moringa oleifera Seeds and Oil: Characteristics and Uses for Human Health
Previous Article in Special Issue
Epidermal Growth Factor Receptor Status in Circulating Tumor Cells as a Predictive Biomarker of Sensitivity in Castration-Resistant Prostate Cancer Patients Treated with Docetaxel Chemotherapy

Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis

Laboratorio Hematologia Oncologica y de Transplantes, Institut Investigacions Biomèdiques (IBB) Sant Pau, Hospital de la Santa Creu i Sant Pau, 08025 Barcelona, Spain
Institut National de la Santé et de la Recherche Médicale (INSERM), Unit 957, Pathophysiology of Bone Resorption and Therapy of Primary Bone Tumours, Equipe Ligue 2012, Faculty of Medicine, University of Nantes, Nantes 44035, France
Department of Oncology and Metabolism, Medical School, University of Sheffield, Beech Hill Road, Sheffield S10 2RX, UK
European Associated Laboratory, INSERM, Sarcoma Research Unit, Medical School, University of Sheffield, Sheffield S10 2RX, UK
Authors to whom correspondence should be addressed.
Academic Editor: Dario Marchetti
Int. J. Mol. Sci. 2016, 17(12), 2142;
Received: 27 September 2016 / Revised: 12 December 2016 / Accepted: 13 December 2016 / Published: 20 December 2016
(This article belongs to the Special Issue Circulating Tumor Cells)
Tumour heterogeneity refers to the fact that different tumour cells can show distinct morphological and phenotypic profiles, including cellular morphology, gene expression, metabolism, motility, proliferation and metastatic potential. This phenomenon occurs both between tumours (inter-tumour heterogeneity) and within tumours (intra-tumour heterogeneity), and it is caused by genetic and non-genetic factors. The heterogeneity of cancer cells introduces significant challenges in using molecular prognostic markers as well as for classifying patients that might benefit from specific therapies. Thus, research efforts for characterizing heterogeneity would be useful for a better understanding of the causes and progression of disease. It has been suggested that the study of heterogeneity within Circulating Tumour Cells (CTCs) could also reflect the full spectrum of mutations of the disease more accurately than a single biopsy of a primary or metastatic tumour. In previous years, many high throughput methodologies have raised for the study of heterogeneity at different levels (i.e., RNA, DNA, protein and epigenetic events). The aim of the current review is to stress clinical implications of tumour heterogeneity, as well as current available methodologies for their study, paying specific attention to those able to assess heterogeneity at the single cell level. View Full-Text
Keywords: heterogeneity; circulating tumour cells; single cells heterogeneity; circulating tumour cells; single cells
Show Figures

Figure 1

MDPI and ACS Style

Tellez-Gabriel, M.; Ory, B.; Lamoureux, F.; Heymann, M.-F.; Heymann, D. Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis. Int. J. Mol. Sci. 2016, 17, 2142.

AMA Style

Tellez-Gabriel M, Ory B, Lamoureux F, Heymann M-F, Heymann D. Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis. International Journal of Molecular Sciences. 2016; 17(12):2142.

Chicago/Turabian Style

Tellez-Gabriel, Marta, Benjamin Ory, Francois Lamoureux, Marie-Francoise Heymann, and Dominique Heymann. 2016. "Tumour Heterogeneity: The Key Advantages of Single-Cell Analysis" International Journal of Molecular Sciences 17, no. 12: 2142.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop